12 result(s)
Arrayed siRNA screens are a powerful tool to look at very precise perturbations in cellular pathways.
Revvity’s Dharmacon™ CRISPR portfolio expands with validated CRISPR guide RNAs for complex but critical gene targets, as well as DNA cutting controls for screen normalization in sensitive assays.
Functional Genomic and Cell Panel Screening can individually provide comprehensive data sets to support therapeutic development, but when utilized in combination they identify novel targets which are cross-validated by independent approaches.
The reasoning and research behind our Dharmacon™ CRISPRi platform recently published in The CRISPR Journal.
Learn about Horizon's CRISPRsc (CRISPR single cell) platform that combines the flexibility of pooled screening with the power of transcriptomics at single cell resolution.
Here we discuss a recent paper by Gisela Jimenez-Duran and colleagues highlighting how a whole genome CRISPR knockout screen, carried out by Horizon Discovery, has enabled identification of a pre-existing inhibitor that can regulate pro-inflammatory macrophages.
A summary of a recent publication in The CRISPR Journal showing that Horizon's integrated pooled CRISPRko and high throughput cell panel screening platform together offer clinically relevant information for therapeutic targets.
Here we talk about the role of the Edit-R Pooled sgRNA Indexing PCR Primers and answer the most common questions about the Indexing PCR and Sequencing Primer kit.
Quantitative measurement removes the guesswork from siRNA transfection optimization